Quantcast

Latest Centocor Stories

2014-06-19 08:28:47

-- Deals span new approaches for cancer, diabetes, autoimmune disease and Alzheimer's, exciting technologies such as 3-D printing for trauma use, sedation monitoring, cardiac remodeling, probiotics for skin infections -- NEW BRUNSWICK, N.J., June 19, 2014 /PRNewswire/ -- Johnson & Johnson Innovation, LLC today announced 12 new alliances with life science companies and research institutions around the globe to explore early-stage innovation in a broad range of therapeutic areas and across...

2014-06-14 23:01:22

The Firm is representing hundreds of women who have filed vaginal mesh lawsuits against Johnson & Johnson’s Ethicon unit in state and federal courts. New York, New York (PRWEB) June 14, 2014 As the litigation surrounding vaginal mesh complications (http://www.transvaginalmeshlawsuithelp.com/transvaginal-mesh-complications/) allegedly caused by devices used to treat pelvic organ prolapse and stress urinary incontinence continues to grow, Bernstein Liebhard LLP notes that the Illinois...

2014-05-22 08:30:31

- More than 30 major product filings planned through 2016 NEW BRUNSWICK, N.J., May 22, 2014 /PRNewswire/ -- At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson (NYSE: JNJ) will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets. Creating Value through...

2014-05-09 16:24:31

Study Evaluating Novel Investigational IL-17 Receptor Antibody Meets All Primary and Secondary Endpoints THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1(TM) study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. Brodalumab is the only investigational treatment in development that binds to the...

2014-05-05 12:28:40

European Dermatologists Indicate that Fewer than Half of Their Severe Patients are being Treated with a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., May 5, 2014 /PRNewswire/ -- Decision Resources Group finds that the use of biologics for the treatment of psoriasis among dermatologists has remained relatively flat since 2011 in the major European markets (France, Germany, Italy, Spain and the United Kingdom), with less than half of severe patients being...

2014-04-29 08:36:39

NEW BRUNSWICK, N.J., April 29, 2014 /PRNewswire/ -- Johnson & Johnson today announced that its affiliate Janssen Pharmaceutica NV (Janssen) has entered into a novel collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership's Global Drug Facility (GDF), to facilitate access to the Company's anti-tuberculosis medicine. This public-private partnership was established by the newly formed Janssen Global Public Health...

2014-04-23 16:29:12

NEW BRUNSWICK, N.J., April 23, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Medical Devices & Diagnostics business for the investment community beginning at 9:30 a.m. (Eastern Time) on Thursday, May 22, 2014 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 2:30 p.m. Dominic J. Caruso, Vice President, Finance and Chief Financial Officer will host the meeting which will feature presentations by Johnson &...

2014-03-24 08:28:42

Results from Phase 2b X-PLORE Study through Week 40 Report Efficacy of Guselkumab across Multiple Dosing Regimens and Compared with Adalimumab DENVER, March 24, 2014 /PRNewswire/ -- New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86 percent of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician's Global Assessment (PGA) score of cleared or minimal at week 16, the...

2014-03-21 23:03:40

ResearchMoz.us include new market research report "PharmaPoint: Crohns Disease - China Drug Forecast and Market Analysis to 2022" to its huge collection of research reports. Browse full report - http://www.researchmoz.us/pharmapoint-crohns-disease-china-drug-forecast-and-market-analysis-to-2022-report.html. Albany, NY (PRWEB) March 21, 2014 The Crohns disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the...

2014-02-25 08:31:42

NEW BRUNSWICK, N.J., Feb. 25, 2014 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the 2014 Cowen 34(th) Annual Health Care Conference on Tuesday, Mar. 4, at The Boston Marriott Copley Place. Dominic Caruso, Vice President, Finance & Chief Financial Officer will represent the Company in a session scheduled at 10:00 a.m. (Eastern Time). This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.